Sarcopenia Treatment Market Set for Significant Growth by 2034: Trends, Insights, and Forecast | DelveInsight

Sarcopenia is a progressive condition characterized by the loss of skeletal muscle mass, strength, and function, primarily affecting the elderly population and significantly impacting mobility, independence, and overall quality of life. As global populations age, sarcopenia is emerging as a critical public health concern, necessitating timely diagnosis and effective management strategies to mitigate its adverse effects.

DelveInsight's latest report, "Sarcopenia - Market Insight, Epidemiology, and Market Forecast - 2034," offers a comprehensive evaluation of the disease landscape across key regions including the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report includes detailed epidemiological analysis segmented by age groups, severity, comorbidities, and risk factors, providing a clear understanding of sarcopenia's burden worldwide.

The sarcopenia treatment market is anticipated to witness steady growth through 2034, driven by rising awareness, improved diagnostic criteria, and advancements in therapeutic options. Innovations in pharmacological treatments, such as myostatin inhibitors and selective androgen receptor modulators (SARMs), alongside non-pharmacological interventions including resistance training and nutritional supplementation, are shaping the evolving care landscape.

Increased emphasis on early detection through screening programs and emerging biomarkers is facilitating better patient stratification and personalized treatment approaches. Additionally, growing research into regenerative therapies and combination treatment modalities holds promise for improving muscle regeneration and functional outcomes.

DelveInsight forecasts that the sarcopenia treatment market will expand significantly, propelled by demographic shifts, enhanced clinical guidelines, and ongoing pipeline developments. Collaborative efforts between researchers, clinicians, and industry stakeholders will be pivotal in advancing therapeutic innovation and addressing the unmet needs of sarcopenia patients globally through 2034.

Request a sample and uncover the latest breakthroughs shaping the sarcopenia treatment market landscape and future outlook @ https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Sarcopenia Treatment Market Report:
• The sarcopenia market in the 7MM was valued at approximately USD 2.2 billion in 2024 and is expected to grow throughout 2025-2034.
• The US held the largest share in 2025, with a market size of around USD 1.5 billion, projected to rise by 2034.
• Diagnosed sarcopenia cases in the 7MM reached nearly 19.8 million in 2024, with an upward trend forecasted through 2034.
• In the US, the highest sarcopenia prevalence in 2024 was among the 65-69 age group, with about 4.5 million diagnosed patients.
• In January 2025, TNF Pharmaceuticals announced that it had achieved a key safety data milestone supporting expanded and longer-term clinical studies of isomyosamine in multiple indications.
• In December 2024, TNF Pharmaceuticals presented positive top-line results from a Phase IIa study of its lead drug candidate MYMD-1 at a prestigious international congress of global experts in sarcopenia and related disorders.
• In December 2024, Lipocine Inc. received FDA Fast Track Designation for LPCN 1148, an oral testosterone prodrug, aimed at treating sarcopenia in patients with decompensated cirrhosis. This designation facilitates expedited development and review processes
• In December 2024, TNF Pharmaceuticals initiated a trial to assess the efficacy of its TNF-α inhibitor, MYMD-1, in treating sarcopenia and frailty induced by GLP-1 weight loss drugs like WEGOVY and OZEMPIC. The study aims to evaluate TNF-α levels in patients exhibiting increased inflammation associated with sarcopenia..
• Emerging therapies for sarcopenia include MYMD-1/ Iisomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510, OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others.
• Key companies involved in the treatment of sarcopenia include MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.

To know in detail about the sarcopenia treatment market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sarcopenia Overview
Sarcopenia is a progressive condition characterized by the loss of skeletal muscle mass, strength, and function, primarily affecting older adults. It significantly impacts mobility, physical performance, and quality of life, increasing the risk of falls, fractures, and disability. The condition is influenced by aging, hormonal changes, inflammation, nutritional deficiencies, and sedentary lifestyles.

As global populations age, sarcopenia is emerging as a major public health concern, driving increased demand for effective diagnosis, management, and treatment options. Current approaches include resistance training, nutritional interventions, and pharmacological therapies aimed at improving muscle mass and function.

Advancements in the sarcopenia treatment market focus on innovative therapies such as anabolic agents, myostatin inhibitors, and regenerative medicine to address underlying mechanisms and enhance patient outcomes. Growing awareness, improved diagnostic criteria, and ongoing clinical research are expected to shape the future landscape of sarcopenia management.

Get a free sample for the sarcopenia treatment market forecast, size & share analysis report: https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sarcopenia Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Sarcopenia Epidemiology Segmentation:
The sarcopenia treatment market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total diagnosed prevalent cases of sarcopenia
• Gender-specific diagnosed prevalent cases of sarcopenia
• Age-specific diagnosed prevalent cases of sarcopenia
• Severity -specific diagnosed prevalent cases of sarcopenia

Sarcopenia Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Sarcopenia throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Sarcopenia drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Sarcopenia, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Sarcopenia therapeutics.

Explore how emerging sarcopenia therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sarcopenia Market Outlook
Currently, sarcopenia is primarily managed through nutritional support, physical therapy, and lifestyle changes, as there are no approved drugs specifically for the condition. The main objective of sarcopenia treatment is to maintain or restore muscle mass and function, thereby improving quality of life and reducing risks like falls and fractures. Due to its complex nature, effective management involves a combination of nutrition, exercise, and, in some cases, pharmacological interventions.

Nutritional strategies focus on adequate protein intake, vitamin D supplementation, and, occasionally, hormone replacement therapy to address hormonal imbalances and support musculoskeletal health. While steroid hormones such as testosterone and anabolic steroids have shown some benefits, their use is limited due to side effects.

The sarcopenia treatment market currently lacks advanced-stage drug candidates; however, promising pipeline therapies like TNF Pharmaceuticals' MYMD-1, Lipocine's LPCN 1148, and Biophytis' BIO101 are expected to shape future growth. According to DelveInsight, these emerging therapies, alongside supportive care, are projected to drive significant expansion in the sarcopenia treatment market from 2025 to 2034.

In 2024, the total sarcopenia treatment market size in the 7MM was approximately USD 2.2 billion and is anticipated to grow steadily. Within the EU4 and the UK, the UK holds the largest market share, while Spain accounts for the smallest. Supportive care therapies are expected to generate the highest revenue across the 7MM by 2034.

Sarcopenia Market Drivers
• The increasing global elderly population drives demand for effective sarcopenia treatments, as muscle loss and weakness are common age-related issues impacting quality of life.
• Enhanced awareness among healthcare providers and improved diagnostic methods are leading to earlier detection and management of sarcopenia, boosting market growth.

Sarcopenia Market Barriers
• The absence of FDA-approved drugs specifically for sarcopenia limits treatment options and slows market expansion.
• Sarcopenia's multifactorial nature requires comprehensive approaches, including lifestyle changes and nutrition, which can hinder consistent treatment adherence and market uptake.

Scope of the Sarcopenia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Sarcopenia Companies: MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Rejuvenate Biomed, Oncocross Therapeutics, OPKO health, NMD Pharma, Rubedo Life Sciences, Immunoforge, and others.
• Key Sarcopenia Therapies: MYMD-1/ Iisomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510, OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others.
• Sarcopenia Therapeutic Assessment: Sarcopenia currently marketed, and Sarcopenia emerging therapies.
• Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Sarcopenia Unmet Needs, KOL's views, Analyst's views, Sarcopenia Market Access and Reimbursement.

To learn more about companies working in the sarcopenia treatment market, visit @ https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Sarcopenia Market Report Introduction
2. Executive Summary for Sarcopenia
3. SWOT analysis of Sarcopenia
4. Sarcopenia Patient Share (%) Overview at a Glance
5. Sarcopenia Market Overview at a Glance
6. Sarcopenia Disease Background and Overview
7. Sarcopenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Sarcopenia
9. Sarcopenia Current Treatment and Medical Practices
10. Sarcopenia Unmet Needs
11. Sarcopenia Emerging Therapies
12. Sarcopenia Market Outlook
13. Country-Wise Sarcopenia Market Analysis (2020-2034)
14. Sarcopenia Market Access and Reimbursement of Therapies
15. Sarcopenia Market Drivers
16. Sarcopenia Market Barriers
17. Sarcopenia Appendix
18. Sarcopenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.